Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
57 hedge funds and large institutions have $240M invested in Syros Pharmaceuticals, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 19 closing their positions.
199% more call options, than puts
Call options by funds: $332K | Put options by funds: $111K
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
55% more capital invested
Capital invested by funds: $154M → $240M (+$85.7M)
17% less funds holding
Funds holding: 69 → 57 (-12)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$11.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.67M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$7.33M |
| 4 |
BlackRock
New York
|
+$3.88M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
-$4.95M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.88M |
| 3 |
CC
Casdin Capital
New York
|
-$2.67M |
| 4 |
AIC
AWM Investment Company
New York
|
-$632K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$330K |
SYRS Hedge Fund Activity: Q1 2018 in Review
57 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2018, worth a combined $240M — up 55% from $154M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of SYRS and 7 opened new positions — a net loss of 12 holders — while 10 trimmed existing stakes and 27 added.
The largest buyer was Redmile Group, adding an estimated $11.1M. The largest seller was Aisling Capital, exiting entirely with an estimated $4.95M sold.
- 57 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2018, down from 69 in Q4 2017.
- Funds reported $240M of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2018, up 55% quarter-over-quarter.
- 7 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2018 and 19 closed out, a net change of -12 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2018 was Redmile Group, an estimated $11.1M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2018 was Aisling Capital, an estimated $4.95M sold.
Based on aggregated 13F filings for Q1 2018.